

Index

Note: Page numbers of article titles are in **boldface** type.

A

AAN. See *American Academy of Neurology (AAN)*.

ABI. See *Ankle-brachial index (ABI)*.

Age, as factor in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 683–684

American Academy of Neurology (AAN), 660

Amputation

in diabetics, prosthetic rehabilitation issues in, **689–703**. See also *Prosthetic rehabilitation issues, in diabetic and dysvascular amputees*.

in dysvascular patients

general outcomes, 678

preoperative rehabilitation evaluation prior to, **677–688**

multidisciplinary approach to, 678–680

patient education in, 686–687

patient history in, 680–684

age, 683–684

cardiopulmonary status and obesity, 682–683

cognition, 681–682

contralateral limb status, 684

ESRD, 683

home environment, 684

premorbid functional status in, 681

psychological history, 681–682

social support, 684

vision, 682

physical examination in, 685–686

prosthetic rehabilitation issues in, **689–703**. See also *Prosthetic rehabilitation issues, in diabetics and dysvascular amputees*.

Amputee(s), diabetic and dysvascular, prosthetic rehabilitation issues in, **689–703**. See also *Prosthetic rehabilitation issues, in diabetics and dysvascular amputees*.

Angiogenic growth factors, in PAD management, 642

Angiography

computed tomography, in PAD diagnosis, 635–636

magnetic resonance, in PAD diagnosis, 635–637

Ankle-brachial index (ABI), in PAD assessment, 628, 632–633

Antibiotic(s)

in diabetic foot infections management, 618–619

topical, in diabetic foot infections management, 619–620

Antiplatelet agents, in PAD management, 638–639

Appraisal(s), of chronic pain in dysvascular and diabetic patients, 706–709

Arterial duplex, in PAD diagnosis, 635

Arteriography, contrast, in PAD diagnosis, 637
 ATP III. See *Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III)*.

B

Behavior(s), illness, operant model of pain and, 711–712

C

Cardiac rehabilitation

- clinical and physiologic benefits of, 720–722
- contraindications to, 722–724
- cost-effectiveness of, 728
- exercise protocols in, 724–726
- goals of, 726–728
- indications for, 722–724
- safety of, 722–724
- success of, measures of, 726–728
- underuse of, 728–729
- update on, **719–736**

Cardiopulmonary status, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 682–683

Cardiovascular disease

- chronic spinal cord dysfunction and, **737–747**. See also *Spinal cord injury (SCI), chronic, cardiovascular disease in persons with*.
- in general population, recommendations for, 738–739

Catastrophizing, of chronic pain in dysvascular and diabetic patients, 708–709

Chronic pain, in dysvascular and diabetic patients, psychosocial factors in, **705–717**. See also *Psychosocial factors, in chronic pain in dysvascular and diabetic patients*.

Cilostazol, in PAD management, 641–642

Claudication

- intermittent, in PAD, 628–630
- revascularization for, 642–643

Claudication rehabilitation

- barriers to, 646–647
- update on, **644–647**

CLI. See *Critical limb ischemia (CLI)*.

Cognition, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 681–682

Computed tomography angiography (CTA), in PAD diagnosis, 635–636

Contralateral limb, status of, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 684

Contrast arteriography, in PAD diagnosis, 637

Coping, pain-related, in dysvascular and diabetic patients, 706–709

Critical limb ischemia (CLI)

- management of, invasive therapies in, 644
- PAD and, 630–631

CTA. See *Computed tomography angiography (CTA)*.

D

Depression, pain and, 709–711

Diabetes mellitus

amputation in patients with, prosthetic rehabilitation issues in, **689–703**. See also *Prosthetic rehabilitation issues, in diabetics and dysvascular amputees*.

cardiovascular disease in persons with, 740–741

chronic pain in patients with, psychosocial factors in, **705–717**. See also *Psychosocial factors, in chronic pain in dysvascular and diabetic patients*.

incidence of, 595–596

PAD and, management of, 640

prevalence of, 595

Diabetic foot, microbiology of, 613–614

Diabetic foot infections, **611–625**

diagnosis of, 612–617

initial assessment in, 612–613

microbiology in, 613–614

wound cultures in, 614–615

evaluation of, published guidelines for, 612

IDSA on, 612

osteomyelitis

diagnosis of, 615–617

treatment of, 620–621

prevalence of, 611

risk factors for, 611–612

treatment of, 617–621

antibiotics in, 618–619

topical, 619–620

duration in, 619

general approach to, 617

optimal approach to, factors complicating establishment of, 617–618

published guidelines for, 612

surgical, determination of need for, 620

venue of, 618

Diabetic foot ulcerations

described, 595–596

pathogenesis of, 596–597

prevention of, **595–609**

cost-effectiveness of, 605–606

interventions for, 598–605

abnormal plantar pressure distribution evaluation and treatment, 600

combined/complex interventions, 602, 605

glycemic control, 598

PAD evaluation and treatment, 598–599

patient education, 601

peripheral neuropathy evaluation and treatment, 599–600

provider education, 602

screening foot examination, 600

skin temperature monitoring, 602

specialized footwear, 601

risk factors of, 597

Diabetic patients, foot ulceration in patients with. See *Diabetic foot ulcerations*.

Diabetic peripheral neuropathy (DPN)

classification of, 664–668

focal neuropathies, 667–668

generalized symmetric neuropathies, 665–667

multifocal neuropathies, 667–668

rapidly reversible hyperglycemia, 665

clinical characteristics of, 658–660

defined, 658

described, 657

diagnosis of, 660–662

electrodiagnosis of, 662–664

in dysvascular patients, **657–676**

pathogenesis of, 668–671

prevalence of, 657

signs of, 659–660

staging of, 660

symptoms of, 658–659

treatment of, 671–674

pathogenic, 671–672

symptomatic, 672–674

Distal symmetric polyneuropathy (DSPN), 658

DPN. See *Diabetic peripheral neuropathy (DPN)*.

DSPN. See *Distal symmetric polyneuropathy (DSPN)*.

Dyslipidemia, PAD-related, management of, 640

Dysvascular patients

amputation in patients with

general outcomes, 678

prosthetic rehabilitation issues in, **689–703**. See also *Prosthetic rehabilitation issues, in diabetics and dysvascular amputees*.

chronic pain in, psychosocial factors in, **705–717**. See also *Psychosocial factors, in chronic pain in dysvascular and diabetic patients*.

disease types, 677

DPN in, **657–676**. See also *Diabetic peripheral neuropathy (DPN)*.

preoperative rehabilitation evaluation of, prior to amputation, **677–688**. See also *Amputation, in idysvascular patients, preoperative rehabilitation evaluation of*.

E

End-stage renal disease (ESRD), in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 683

Energy requirements, of diabetics and dysvascular amputees, prosthetic rehabilitation issues, 697

Environment(s), home, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 684

ESRD. See *End-stage renal disease (ESRD)*.

Exercise

in cardiac rehabilitation, 724–726

in PAD management, 647–649

F

Focal neuropathies, 667–668

Foot, diabetic, microbiology of, 613–614

Foot infections, diabetic, **611–625**. See also *Diabetic foot infections*.

Foot ulceration(s), diabetic. See *Diabetic foot ulcerations*.

Footwear

in diabetics and dysvascular amputees, prosthetic rehabilitation issues, 695–696

specialized, in prevention of diabetic foot ulcerations, 601

Functional impairment, asymptomatic, PAD and, 630

Functional status, premorbid, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 681

G

Generalized symmetric neuropathies, 665–667

Glucose tolerance, impaired, cardiovascular disease in persons with, 740–741

Glycemic control, in prevention of diabetic foot ulcerations, 598

H

Home environment, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 684

Hyperglycemia

DPN due to, 668–669

rapidly reversible, 665

Hypertension, PAD-related, management of, 640–641

I

IDSAs. See *Infectious Diseases Society of America (IDSA)*.

Illness behaviors, operant model of pain and, 711–712

Infection(s), foot, diabetic, **611–625**. See also *Diabetic foot infections*.

Infectious Diseases Society of America (IDSA), on diabetic foot infections, 612

Ischemia(s)

critical limb

management of, invasive therapies in, 644

PAD and, 630–631

DPN due to, 669–670

L

Leg(s), PAD effects on, 628–630

Lifestyle modification, in PAD management, 643

Limb loss, SCI, peripheral vascular disease and, 742–745

Lipid metabolism, coronary heart disease and, 739–740

M

Magnetic resonance angiography (MRA), in PAD diagnosis, 635–637

Medicare, functional level of, prosthetic componentry for diabetics and dysvascular amputees and, 697–698

Metabolic syndrome, chronic SCI and, 741

MRA. See *Magnetic resonance angiography (MRA)*.

Multifocal neuropathies, 667–668

N

NDS. See *Neurologic Disability Score (NDS)*.

Neurologic Disability Score (NDS), 660

Neurology Symptoms Score (NSS), 660

Neuropathy(ies)

focal, 667–668

generalized symmetric, 665–667

multifocal, 667–668

peripheral. See *Peripheral neuropathy*.

diabetic. See *Diabetic peripheral neuropathy (DPN)*.

NSS. See *Neurology Symptoms Score (NSS)*.

O

Obesity

cardiovascular disease in persons with, 742

chronic SCI and, 742

evaluation of, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 682–683

Osteomyelitis, diabetic foot

diagnosis of, 615–617

treatment of, 620–621

P

PAD. See *Peripheral arterial disease (PAD)*.

Pain

chronic, in dysvascular and diabetic patients, psychosocial factors in, **705–717**. See also *Psychosocial factors, in chronic pain in dysvascular and diabetic patients*.

depression due to, 709–711

in dysvascular and diabetic patients, 705–706

management of, in diabetics and dysvascular amputees, prosthetic rehabilitation issues, 695

operant model of, illness behaviors and, 711–712

Patient education

for diabetics and dysvascular amputees, prosthetic rehabilitation issues, 691–693

in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 686–687

in prevention of diabetic foot ulcerations, 601

Pentoxifylline, in PAD management, 642

Peripheral arterial disease (PAD)

asymptomatic functional impairment in, 630

atypical leg symptoms in, 628–630

awareness of, 649–650

- cardiovascular outcomes of, 631
- CLI in, 630–631
- clinical manifestations of, 628–631
- described, 627
- diagnosis of
 - ABI in, 632–633
 - arterial duplex in, 635
 - contrast arteriography in, 637
 - CTA in, 635–636
 - MRA in, 635–637
 - noninvasive, 632–637
 - patient history in, 632
 - physical examination in, 632
 - physiologic testing in, noninvasive, 633–635
- epidemiology of, 627–628
- evaluation of, 598–599
 - ABI index in, 628
- intermittent claudication in, 628–630
- limb outcomes of, 631–632
- management of, 598–599
 - angiogenic growth factors in, 642
 - antiplatelet agents in, 638–639
 - cilostazol in, 641–642
 - claudication rehabilitation in, 644–647
 - dyslipidemia and, 640
 - exercise training in, recommendations for, 647–649
 - functional status-related, 641–643
 - hypertension-related, 640–641
 - in diabetics, 640
 - lifestyle modification in, 643
 - limb preservation in, 644
 - medical, 637–644
 - pentoxifylline in, 642
 - pharmacologic, 641–642
 - prostaglandins in, 642
 - quality of life-related, 641–643
 - smoking cessation in, 639–640
 - systemic atherosclerosis treatment for cardiovascular risk reduction in, 638–641
- natural history of, 631–632
- prevalence of, 627–628
- risk factors for, 627–628
- update on, **627–656**
- Peripheral neuropathy
 - diabetic. See *Diabetic peripheral neuropathy (DPN)*.
 - evaluation of, in prevention of diabetic foot ulcerations, 599–600
 - treatment of, in prevention of diabetic foot ulcerations, 599–600
- Peripheral vascular disease, SCI and, limb loss due to, 742–745
- Plantar pressure, distribution of, abnormal, evaluation and treatment of, in prevention of diabetic foot ulcerations, 600
- Polyneuropathy, distal symmetric, 658

- Premorbid functional status, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 681
- Preprosthetic therapy program, in diabetics and dysvascular amputees, 693–694
- Prostaglandin(s), in PAD management, 642
- Prosthetic(s), in diabetics and dysvascular amputees
 - components of, 697–700
 - design of, 698–700
 - training for, 700–701
- Prosthetic rehabilitation issues, in diabetics and dysvascular amputees, **689–703**
 - complications, 701
 - energy requirements, 697
 - footwear, 695–696
 - Medicare functional level, 697–698
 - pain management, 695
 - patient education, 691–693
 - postoperative evaluation, 689–691
 - preprosthetic therapy program, 693–694
 - prosthetic componentry, 697–700
 - prosthetic training, 700–701
 - time frame of rehabilitation, 696–697
 - wound care, 694–695
- Provider education, in prevention of diabetic foot ulcerations, 602
- Psychological factors, in preoperative rehabilitation evaluation of dysvascular patient prior to amputation, 681–682
- Psychosocial factors, in chronic pain in dysvascular and diabetic patients, **705–717**
 - appraisals, 706–709
 - catastrophizing, 708–709
 - coping, 706–709
 - depression, 709–711
 - fear of movement/reinjury, 706–708
 - operant model of pain, 711–712

Q

- QAFT. See *Quantitative Autonomic Function Testing (QAFT)*.
- Quality of life, in PAD management, 641–643
- Quantitative Autonomic Function Testing (QAFT), 660

R

- Rapidly reversible hyperglycemia, 665
- Rehabilitation
 - cardiac, update on, **719–736**. See also *Cardiac rehabilitation*.
 - claudication
 - barriers to, 646–647
 - update on, 644–647
 - prosthetic, issues related to, in diabetics and dysvascular amputees, **689–703**. See also *Prosthetic rehabilitation issues, in diabetics and dysvascular amputees*.
- Renal disease, end-stage, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 683

S

SCI. See *Spinal cord injury (SCI)*.

Skin temperature, monitoring of, in prevention of diabetic foot ulcerations, 602

Smoking

cessation of, in PAD management, 639–640

SCI and, 740

Social support, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 684

Spinal cord injury (SCI), chronic

cardiovascular disease in persons with, **737–747**

chronic

cardiovascular disease in persons with

concerns related to, 739

diabetes mellitus and, 740–741

impaired glucose tolerance and, 740–741

lipid metabolism and, 739–740

obesity and, 742

peripheral vascular disease and, 742–745

metabolic syndrome and, 741

smoking and, 740

epidemiology of, 737–738

T

Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III), 738

U

Ulcer(s), foot, diabetic, pathogenesis of, 596–597

Ulceration(s), diabetic foot. See *Diabetic foot ulcerations*.

V

Vascular disease, peripheral, SCI and, limb loss due to, 742–745

Vision, assessment of, in preoperative rehabilitation evaluation of dysvascular patients prior to amputation, 682

W

Wound care, in diabetics and dysvascular amputees, prosthetic rehabilitation issues, 694–695

Wound cultures, in diabetic foot infections diagnosis, 614–615